Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B D Green

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Infection and Immunity|August 1, 1985
Demonstration of a capsule plasmid in Bacillus anthracisB D Green, L Battisti, T M Koehler, et al.
Peptides|December 21, 2010
Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in ratsA Agnew, D Calderwood, O P Chevallier, et al.
Molecular Microbiology|November 1, 1994
Characterization of spo0A homologues in diverse Bacillus and Clostridium species identifies a probable DNA-binding domainD P Brown, L Ganova-Raeva, B D Green, et al.
Archives of Biochemistry and Biophysics|July 13, 2004
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acidB D Green, V A Gault, P R Flatt, et al.
Diabetologia|March 11, 2003
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretinV A Gault, F P M O'Harte, P Harriott, et al.
The Journal of Endocrinology|April 23, 2005
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob miceB D Green, N Irwin, V A Gault, et al.
International Journal of Andrology|November 1, 2007
Metabolic profile changes in the testes of mice with streptozotocin-induced type 1 diabetes mellitusC Mallidis, B D Green, D Rogers, et al.
Diabetes, Obesity & Metabolism|July 30, 2005
Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1B D Green, H K Liu, J T McCluskey, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
The Journal of Endocrinology|March 12, 2004
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Infection and Immunity|August 1, 1985
Demonstration of a capsule plasmid in Bacillus anthracisB D Green, L Battisti, T M Koehler, et al.
Peptides|December 21, 2010
Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in ratsA Agnew, D Calderwood, O P Chevallier, et al.
Molecular Microbiology|November 1, 1994
Characterization of spo0A homologues in diverse Bacillus and Clostridium species identifies a probable DNA-binding domainD P Brown, L Ganova-Raeva, B D Green, et al.
Archives of Biochemistry and Biophysics|July 13, 2004
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acidB D Green, V A Gault, P R Flatt, et al.
Diabetologia|March 11, 2003
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretinV A Gault, F P M O'Harte, P Harriott, et al.
The Journal of Endocrinology|April 23, 2005
Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob miceB D Green, N Irwin, V A Gault, et al.
International Journal of Andrology|November 1, 2007
Metabolic profile changes in the testes of mice with streptozotocin-induced type 1 diabetes mellitusC Mallidis, B D Green, D Rogers, et al.
Diabetes, Obesity & Metabolism|July 30, 2005
Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1B D Green, H K Liu, J T McCluskey, et al.
Metabolism: Clinical and Experimental|February 10, 2004
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)B D Green, M H Mooney, V A Gault, et al.
The Journal of Endocrinology|March 12, 2004
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activityB D Green, M H Mooney, V A Gault, et al.
Pageof 4